NATALIE TSIGONIS: Open Payments
NPI 1659301836 · STRATFORD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$825 in 34 payments from 7 companies in 2025. Trend: 2023 $859 · 2024 $1,144 · 2025 $825
Food & beverage: $825
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $367 |
| ABBVIE INC. | 14 | $263 |
| Collegium Pharmaceutical, Inc. | 4 | $61 |
| Lilly USA, LLC | 3 | $47 |
| Novo Nordisk Inc | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| HARMONY BIOSCIENCES LLC | 1 | $17 |
Products named: AIRSUPRA, QULIPTA, XTAMPZA, UBRELVY, FARXIGA, VRAYLAR, MOUNJARO, ZORYVE.
Industry payments across NJ — which companies pay providers there.
